In this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass look at the recent earnings report from biotech company Celgene (NASDAQ:CELG), to sift out the vital numbers that investors need to know.

The guys note that while the top line for Celgene came in a little light, the company did beat on bottom line estimates. Despite phenomenal sales growth numbers for key drugs Revlimid, Abraxane, and Pomalyst, David also mentions that this may be an unfortunate case of the market's expecting even more from a star performer. David also discusses the company's deal with Nogra Pharma for the development and marketing of an experimental Crohn's disease drug, and looks ahead to one crucial court date for Revlimid that could be a huge blow to Celgene if the court decision doesn't go in the company's favor.

Warren Buffett just bought nearly 9 million shares of this company
Imagine a company that rents a very specific and valuable piece of machinery for $41,000 per hour. (That's almost as much as the average American makes in a year!) And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click here to discover more about this industry-leading stock, and join Buffett in his quest for a veritable landslide of profits!

David Williamson and Michael Douglass have no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.